Key Takeaways
- Battery chemicals hit its stride: Q2 battery revenue jumped to ₹37 crore (vs ₹5 crore YoY), and management expects a significantly better Q3 and an even stronger Q4 as non-China sourcing requirements begin.
- Base business raised the floor: H1 base business already crossed ₹550 crore, prompting an FY27 base revenue guidance upgrade to ₹1,100 crore+ (from ₹950–1,050 crore), with Dahej's rebuild unlocking further CSM projects.
- The US non-FEOC catalyst is now a timeline, not a thesis: By June next year, Neogen expects access to the entire US electrolyte ecosystem, with three of five producers already audited and two in commercial supply.
- Margins are volatile by design: Consolidated EBITDA grew 51% YoY but margins dipped as Neogen Ionics absorbs fixed costs ahead of volume, and Dahej rebuild expenses persist; management asks for patience while the ecosystem stabilises.
- What to watch next quarter: The pace of Pakhajan's trial production ramp, Exide's electrolyte qualification outcome, and whether Q3 battery revenue delivers the promised sequential jump.
Battery Chemicals: The Inflection Quarter
- Revenue trajectory steepening: Q1 was ~₹17 crore, Q2 reached ₹37 crore, Q3 is expected significantly better, and Q4 even stronger as the non-China requirement starts, driven by US electrolyte manufacturers shifting sourcing to non-FEOC suppliers in India.
- Salt dominates today, electrolyte is the unlock: The majority of H1 battery revenue is salt; electrolyte is less than 5–10% of the mix, but the electrolyte mechanical assembly is complete and trial runs have begun alongside joint recipe trials with multiple giga factories.
- Customer approvals progressing fast: Dahej has been approved by three of five international electrolyte producers, with the fourth expected soon; the fifth customer will directly approve the Pakhajan site. Two international customers have already started commercial supply from Dahej.
- Indian cell makers are moving: Ola has all approvals; Exide is in trials and has announced Q4 commercialisation; Tata, Reliance, Amara Raja, and Waaree are targeting Q4 FY27 to Q1 FY28 for capacity coming online.
- Pakhajan is the next catalyst: Trial production is expected by December 2026, with significant production quantities by February/March 2027; for customers already approved at Dahej, site transfer to Pakhajan will take only 2–3 months.
- FY27 battery guidance held, with a caveat: ₹200 crore from salt and ₹100 crore from electrolyte is maintained; if electrolyte falls short due to Indian customer timing, management will try to make it up with Pakhajan capacity, and any residual shortfall is covered by base business outperformance.
Dr. Harin Kanani: "Q4 is a quarter where we will have the non-China requirement start. So, we are expecting even a stronger Q4."
Base Business: The Silent Outperformer
- H1 already ahead of plan: Base business crossed ₹550 crore in H1, and the second half is usually stronger, supporting the upgraded FY27 base revenue guidance of ₹1,100 crore+ (up from ₹950–1,050 crore).
- Dahej rebuild unlocks pent-up demand: The rebuilt Dahej plant is in trial runs and expected to commence commercial production shortly within the current financial year; this will release CSM projects that were on hold and improve product mix.
- Organolithium is running hot: Active capacity of 300 tonnes (25 tonnes/month) is fully utilised or above, with strong demand from pharma, agro, semiconductor, and specialty polymer applications, including international approvals already received.
- Organolithium capacity doubling approved: The board approved expansion from 300 MTPA to 600 MTPA at Patancheru with capex of up to ₹45 crore, targeted for completion by end of H1 FY28, expected to contribute an additional ₹50–75 crore in FY28 and ₹150–200 crore at full run-rate.
- FY28 base business raised: Now guided at ₹1,200–1,300 crore (enhanced from ~₹1,150 crore), incorporating the Organolithium expansion that was not previously factored in.
Dr. Harin Kanani: "We have already got approvals in both, semiconductor materials as well as for the specialty polymers where also there is a strong volume demand."
The US Non-FEOC Opportunity
- The 45X clock is ticking: Calendar 2027 is the deadline for customers to shift from FEOC (China) to non-FEOC supplies to qualify for the 45X tax credit; Neogen benefits from non-FEOC compliance plus Morita's stable, proven technology.
- US ecosystem access by mid-2027: Three of five US electrolyte producers have completed audits at Dahej, two are already in commercial supply, and by June next year management expects access to the entire US electrolyte ecosystem.
- Chinese competition dismissed as posturing: Management sees Chinese companies setting up in the US as more hope of a policy change than a real threat, arguing that very few customers would be interested in a Chinese-owned or controlled facility under current policy.
Dr. Harin Kanani: "By June next year, we would have access to the entire ecosystem of the U.S."
Margins: Volatility With a Long-Term Logic
- Consolidated EBITDA grew 51% YoY to ₹45 crore, but margins dipped as Neogen Ionics absorbs fixed costs while capacity utilisation ramps up, and Dahej rebuild expenses plus interim tolling arrangements and elevated input costs weigh on profitability.
- The timing mismatch is structural: Capacity coming online causes expenses in one quarter with utilisation following in the next, making exact margin prediction difficult; standalone profitability is better than consolidated because the latter reflects Neogen Ionics' initial fixed cost absorption.
- Neogen Ionics profitability path: Expects to be EBITDA positive once significant volumes come from Q4 FY27 and Q1 FY28, with PBT positive "very soon — sometime in the next financial year."
- Base business margins guided at 18–20%: Management hopes the Dahej plant coming online and improved product mix will improve margins beyond Q4 and into next year.
- Full-utilisation financial target: On ~₹2,500–3,000 crore revenue at full utilisation by FY29, management expects ₹500 crore-plus EBITDA with 20%+ ROCE.
Dr. Harin Kanani: "I know in the beginning this year and next year, the margins, there will be some volatility. But again you can focus on that or you can focus on the opportunity that we have for the next 10 years. As the entire ecosystem and business stabilises we request our investors to be a little bit more patient."
Balance Sheet & Capex: Funding the Buildout
- QIP raised ₹600 crore, oversubscribed 6.5x with broad-based participation; ₹200 crore of bond repayment already completed using the proceeds.
- Insurance claim boost: An additional ₹152 crore was accepted on October 29,2026, bringing total on-account claims received and receivable to ₹316 crore; the ₹152 crore is expected in Q3.
- Morita investment: ₹77 crore already infused through preference allotment; the second instalment is expected by end of Q3 or early Q4.
- Net debt FY28 expected at ₹1,300–1,500 crore, driven by remaining capex (₹308 crore identified) plus working capital for ₹1,000 crore+ battery revenue; interest costs are expected to trend downwards on term debt reduction, lower borrowing costs after the credit rating upgrade, and the incoming insurance claim.
- Inventory elevated by design: The increase is driven by Dahej not yet fully online (requiring continued outsourcing/toll manufacturing) plus significantly increasing customer demand; target inventory days are ~180 by end FY27, declining to 140–160 in FY28 and 110–140 in FY29–30.
- Next capex decision timeline: A call on additional salt capacity will be taken by Q4 FY27/Q1 FY28 based on US and India demand clarity, government localisation policy, and customer security-of-supply approaches; the next leg of electrolyte capacity expansion may be planned in FY29 as management expects to fall short of capacity by FY30.
The 10-Year Capacity Vision
- India's demand trajectory: Battery requirement this year will exceed current capacity; next year demand is expected at ~95–100 GWh; by FY30, 160 GWh is expected against 60 GWh of installed cell capacity.
- Neogen's China-model aspiration: If India reaches where China is today within 10 years, and Neogen holds a 30% market share, that implies ~300 KT electrolyte capacity and ~380 KT salt capacity — approximately 10x current levels — requiring constant capex cycles over the next 7–8 years.
- First-mover moat is real: Management argues it is very difficult for new entrants to set up an electrolyte facility within two years, get approvals, win customer confidence, and price competitively against Neogen's proven technology; the next 30,000-tonne expansion would cost only 60–70% of a greenfield project.
- Electrolyte qualification timelines: For customers shifting site from Dahej to Pakhajan, 2–3 months; for others testing samples, qualification is expected between 2 months and a maximum of 6 months; by March 2027, the electrolyte plant should be fully approved.
- Lithium pricing is pass-through: Existing long-term contracts have quarterly resets; new customers are on monthly resets or fixed 6-month/9-month periods with advances or back-to-back lithium coverage, insulating Neogen from lithium price volatility.
Dr. Harin Kanani: "If within 10 years India reaches where China is today... Neogen also has a 30% kind of market share — based on just looking at the China model, no other logic. That also requires a 300 KT kind of electrolyte capacity and 380 KT salt capacity — approximately 10 times of what we have today."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY27 consolidated revenue | Close to ₹1,350–1,400 crore | FY27 |
| FY27 base business revenue | ₹1,100 crore+ (upgraded from ₹950–1,050 crore) | FY27 |
| FY27 battery revenue | ₹250–300 crore (₹200 crore salt, ₹100 crore electrolyte); ₹300 crore still attempted | FY27 |
| FY28 base business revenue | ₹1,200–1,300 crore (enhanced from ~₹1,150 crore) | FY28 |
| FY28 battery revenue | ₹1,000 crore+; ₹1,200–1,500 crore range depending on electrolyte development | FY28 |
| Organolithium capacity expansion | 300 MTPA to 600 MTPA; capex up to ₹45 crore | Completion by end of H1 FY28 |
| Organolithium revenue contribution | Additional ₹50–75 crore in FY28; ₹150–200 crore at full run-rate | FY28 / FY29 |
| Pakhajan trial production | Trial production begins | December 2026 |
| Pakhajan commercial quantities | Significant production quantities | February/March 2027 |
| Dahej commercial production | Commence commercial production | Within current financial year (FY27) |
| US ecosystem access | Access to entire US electrolyte ecosystem | By June 2027 |
| Neogen Ionics EBITDA positive | EBITDA positive on significant volumes | Q4 FY27 / Q1 FY28 |
| Neogen Ionics PBT positive | PBT positive | Sometime in next financial year (FY28) |
| Full utilisation financial target | ₹500 crore+ EBITDA, 20%+ ROCE on ~₹2,500–3,000 crore revenue | FY29 |
| Net debt FY28 | ₹1,300–1,500 crore | FY28 |
| Inventory days | ~180 days by end FY27; 140–160 days FY28; 110–140 days FY29–30 | FY27–FY30 |
| Salt capacity expansion decision | Decision on additional capacity | By Q4 FY27 / Q1 FY28 |
| Next electrolyte capex decision | Planning for next capacity increase | FY29 (to avoid shortfall by FY30) |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Consolidated revenue | ₹296 crore, up 42% YoY |
| Consolidated EBITDA | ₹45 crore, up 51% YoY |
| Standalone EBITDA | ₹54 crore, up 54% YoY; margin 18.6% |
| Consolidated PAT | ₹8 crore, up 144% YoY |
| Standalone PAT | ₹21 crore, up 127% YoY |
| Battery chemicals revenue | ₹37 crore, vs ₹5 crore in Q2 FY26 |
| Organic chemicals revenue | ₹238 crore, up 29% YoY |
| Inorganic chemicals revenue | ₹58 crore, up 140% YoY |
| Neogen Ionics revenue | ₹27 crore, vs ₹5 crore in Q2 FY26; equal to full-year FY26 sales |
| Consolidated net debt | ₹1,095 crore as of September 30, 2026 |
| Standalone net debt | ₹378 crore as of September 30, 2026 |
| Liquid investments (fixed deposits) | ₹465 crore as of September 30, 2026 |
| FY27 consolidated revenue guidance | ₹1,350–1,400 crore, in line with or slightly better than previous guidance |
| FY27 battery chemicals guidance | ₹250–300 crore, previously ₹300 crore; ₹200 crore from salts, ₹100 crore from electrolyte |
| FY28 battery chemicals guidance | ₹1,000 crore+, range could be ₹1,200–1,500 crore depending on electrolyte |
| FY28 base business guidance | ₹1,200–1,300 crore, enhanced from earlier ~₹1,150 crore; includes Organolithium expansion |
| FY28 consolidated net debt expectation | ₹1,300–1,500 crore, depending on lithium prices |
| Organolithium capacity utilisation | ~25 tonnes per month (300 MTPA fully utilised) |
| Cumulative insurance recoveries to date | ₹164 crore, comprising ₹155 crore on-account payment and ₹9 crore salvage |
| Additional insurance claim accepted | ₹152 crore on October 29, 2026; total claims received and receivable now ₹316 crore |
| QIP fundraise | ₹600 crore, oversubscribed 6.5x |
| Credit rating | CRISIL A- stable (long-term outlook revised from negative), short-term reaffirmed at CRISIL A2+ |
| Organolithium capacity expansion capex | Up to ₹45 crore, doubling capacity from 300 MTPA to 600 MTPA; additional revenue potential ₹150–200 crore |
| Business transfer agreement (NML) | ₹245 crore on a going-concern basis, includes ₹77 crore infused by Morita via preference allotment |
| Inventory days target by end FY27 | ~180 days |
| Battery business working capital cycle target | ~90 days |